Loading stock data…
Corbus Pharmaceuticals Holdings (CRBP)
$10.60-0.48 (-4.38%)
Market ClosedLast close Sep 8
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Corbus Pharmaceuticals Holdings, Inc. in the Healthcare sector is trading at $10.60 with a market capitalization of $195M. Wall Street consensus targets $34.02 (10 analysts), implying a +221.1% move over the next 12 months. The stock is currently 48% below its 52-week high of $20.56, remaining 14.2% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +221.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$36.19M↓ | -$24.30M↓ | -$21.97M↑ | -$24.42M↓ | -$19.15M |
| Net Income | -$35.04M↓ | -$22.97M↓ | -$20.55M↑ | -$23.34M↓ | -$17.66M |
Peer Comparison
JNJUNHPFE
Fundamentals
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to rel...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$195.15M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.62
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-99.67%
Volume
Today's trading volume
915,184
Recent News
Corbus Pharmaceuticals Teases Cancer, Obesity Data as Key Clinical Readouts Near
Corbus Pharmaceuticals (NASDAQ:CRBP) Chief Executive Yuval Cohen outlined the company’s near-term clinical readout schedule and development plans for its two lead drug candidates during a Jefferies fireside chat hosted by biotech analyst Amin Makarem. Cohen said the Norwood, Massachusetts-based dru
Corbus Pharmaceuticals Targets HPV-Linked Head and Neck Cancer With CRB-701 Study
Corbus Pharmaceuticals (NASDAQ:CRBP) executives and oncology specialists used an ASCO-linked discussion to outline the rationale for focusing the company’s CRB-701 program on recurrent or metastatic oropharyngeal head and neck cancer, particularly in patients whose disease is associated with human p
Corbus Pharmaceuticals Teases Key ASCO Cancer Data, Late-Summer Obesity Readout
Corbus Pharmaceuticals (NASDAQ:CRBP) Chief Executive Officer Yuval Cohen said investors should expect more mature clinical updates for CRB-701 at the upcoming ASCO meeting, including the first durability and progression-free survival data for the company’s highlighted cervical and head and neck canc
Spotify upgraded, Alibaba initiated: Wall Street's top analyst calls
Spotify upgraded, Alibaba initiated: Wall Street's top analyst calls
Mizuho Sees Strong Risk-Reward in Corbus Pharmaceuticals Holdings, Inc. (CRBP) Near Cash Value
We recently compiled a list of the 10 Best Biotech Stocks Under $10 to Buy. Corbus Pharmaceuticals Holdings, Inc. is among the best biotech stocks. TheFly reported on April 7 that Mizuho raised its price target on CRBP from $39 to $40 while maintaining an Outperform rating. The firm updated its valuation model following the […]